Search results
Results from the WOW.Com Content Network
Disruptive mood dysregulation disorder (DMDD) is a mental disorder in children and adolescents characterized by a persistently irritable or angry mood and frequent temper outbursts that are disproportionate to the situation and significantly more severe than the typical reaction of same-aged peers.
Ecopipam is currently in a Phase 3 clinical trial for the treatment of Tourette syndrome in children ages 7 to 17 [18] and for the treatment of restless syndrome augmentation (Phase 1/2) [2] Ecopipam is an investigational first-in-class drug also being evaluated for the treatment of childhood-onset fluency disorder in adults. [19]
Fenfluramine, sold under the brand name Fintepla, is a serotonergic medication used for the treatment of seizures associated with Dravet syndrome and Lennox–Gastaut syndrome. [ 3 ] [ 7 ] [ 4 ] It was formerly used as an appetite suppressant in the treatment of obesity , but was discontinued for this use due to cardiovascular toxicity before ...
The one-time therapy, branded as Lenmeldy in the U.S., is approved for children in certain stages of disease progression, the Food and Drug Administration (FDA) said. US approves first gene ...
The diagnosis of bipolar disorder in children has been heavily debated for many reasons including the potential harmful effects of adult bipolar medication use for children. PBD is similar to bipolar disorder (BD) in adults , and has been proposed as an explanation for periods of extreme shifts in mood called mood episodes.
Fluvoxamine, sold under the brand name Luvox among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. [8] It is primarily used to treat major depressive disorder and, perhaps more-especially, obsessive–compulsive disorder (OCD), [9] but is also used to treat anxiety disorders [10] such as panic disorder, social anxiety disorder, and post-traumatic stress ...
In 2010, guanfacine was approved by the FDA for the treatment of attention deficit hyperactivity disorder for people 6 to 17 years old. [16] It was approved for ADHD by the European Medicines Agency under the name Intuniv in 2015. [61] It was added to the Australian Pharmaceutical Benefits Scheme for the treatment of ADHD in 2018. [62]
The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug Administration Dec. 20 press release.